MiNA Therapeutics
Robin was appointed Chief Financial Officer in 2021. He has over three decades of experience in over 250 financing transactions and 170 M&A transactions, with previous CFO roles at listed biopharmaceutical companies Pharming Group NV, Karolinska Development AB and Orexo AB. Prior to this, Robin held senior roles in private equity and investment banking, including Head of European Pharma & Chemicals M&A at Citibank Salomon Smith Barney. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Robin is also non-executive chairman of Vaccitech.
This person is not in any offices
MiNA Therapeutics
Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.